Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada
Wellbeing Digital Sciences, an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, has announced that its wholly-owned subsidiary KGK Science, has been awarded an institution-wide cannabis research license for their new state-of-the-art facility by Health Canada under the Cannabis Act and Cannabis Regulations, allowing the Company to possess cannabis for the purpose of research and development.
The Research License greatly reduces the timelines required for conducting cannabis research and facilitates the ability for KGK to apply for cannabis import permits without first having to obtain project-specific research licenses.
“The Research License allows KGK to conduct clinical trials investigating cannabis for both non-therapeutic and therapeutic purposes, as well as on-site sensory assessments of cannabis products, without having to obtain project specific cannabis research licenses, ultimately accelerating our research programs and reducing the time to market,” added Najla Guthrie, CEO of Wellbeing Digital and KGK Science.
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Read more
- Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs Read more
- Sharecare Launches VR Program to Improve Well-being of American Workforce Read more
- Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer Read more
- Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment Read more